Metastatic prostate cancer patients with an adrenal-permissive variant of the HSD3B1 gene are more likely to have aggressive, early castration-resistant disease and shorter survival, a Cleveland Clinic-led study has found. The finding could help physicians identify patients most likely to benefit from escalated treatment.
See these presentations by Cleveland Clinic Cancer Center staff at ASCO 2019.
If therapies for advanced prostate cancer — particularly those with curative intent for oligometastatic disease — are to progress, clinical trials will need to take into account what’s driving tumor progression, what treatment will add benefit, and for which patients, contends eminent cancer researcher Nima Sharifi, MD.
Please join our staff as we participate or present in the following presentations at the 2019 AUA Annual Meeting.
Cleveland Clinic Glickman Urological & Kidney Institute physicians will make over 75 presentations at this year’s AUA meeting. We look forward to seeing you in Chicago.
Find out what’s next in urologic and kidney disease research — from a diagnostic blood test for prostate cancer to a precision medicine approach to chronic kidney disease.
New findings suggest a noninvasive method of monitoring the metabolic status of prostate tumors in real time and have clear implications for the future of prostate cancer imaging.
Two postdoctoral fellows in the laboratory of Nima Sharifi, MD, have received prestigious Department of Defense Prostate Cancer Research Program Early Investigator Research Awards in support of innovative prostate cancer work.
Recruitment underway to bring additional leading scientists to expanding GU cancer research program at Cleveland Clinic.
Men with the HSD3B1(1245C) variant metabolize abiraterone differently and have high levels of a metabolite called 3-keto-5α-abiraterone.